SARS-CoV-2 serology across scales: a framework for unbiased seroprevalence estimation incorporating antibody kinetics and epidemic recency

Data Availability

Raw antibody data used in this analysis are publicly available in a prior publication (17). Raw serosurvey data are available in the citations in Table 1. Access to COVID-19 seroprevalence data from the Nationwide Commercial Laboratory Seroprevalence Survey is maintained by the Centers for Disease Control and Prevention's (CDC)'s Epi Task Force Seroprevalence Team. Requests for access to the data should be directed to: eocevent452@cdc.gov. The CDC does not take responsibility for the scientific validity or accuracy of methodology, results, statistical analyses, or conclusions presented.